Syndrome  >>  vatalanib (PTK787)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vatalanib (PTK787) / Novartis, Bayer
NCT00052013: Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

Completed
2
11
US
PTK787/ZK 222584
Novartis Pharmaceuticals
Von Hippel-Lindau Disease, CNS Hemangioblastoma, Retinal Hemangioblastoma
06/06
 
PTK787, NCT00590343: Safety and Efficacy Study of /ZK222584 to Treat Metastatic Neuroendocrine Tumors

Completed
2
23
US
vatalanib
Louisiana State University Health Sciences Center in New Orleans, Novartis
Metastatic Neuroendocrine Tumors
03/10
10/10
CPTK787, NCT00627198: The Safety and Efficacy of /ZK222584 in Patients With Metastatic Neuroendocrine Tumors

Completed
2
20
US
PTK787/ZK222584 - Experimental
University of Iowa, Novartis Pharmaceuticals
Neuroendocrine Tumors
11/10
11/10

Download Options